We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Upstate Obtains Rights to Leukemia Biomarker

By Labmedica staff writers
Posted on 13 Apr 2005
The rights to sell the anti-ZAP-70 monoclonal antibody for diagnostic use have been acquired from the University of California, Los Angeles (USA) by the Upstate Group (Charlottesville, VA, USA). More...


The antibody is a key biomarker for chronic lymphocytic leukemia. Studies have shown that the levels of expression of the anti-ZAP-70 protein strongly predict the aggressiveness of the disease. One such study cited this use of the anti-ZAP-70, clone 2F3.2, monoclonal antibody in the May 2003 issue of the New England Journal of Medicine. Scientists used anti-ZAP-70 in immunohistochemistry, flow cytometry, and Western blot analysis of samples from chronic lymphocytic leukemia patients.

"Anti-Zap-70 was formerly only available for research use,” explained Ian Ratcliffe, president of Upstate. "Since the publication of the New England Journal of Medicine study, we have had multiple customer inquiries about its diagnostic or therapeutic use in humans or animals. The recently obtained rights will allow us to work more closely with diagnostic companies active in cell signaling.”

Upstate anticipates significant growth from the biomarker, including the development of ZAP-70 diagnostic kits, development of ZAP-70 as a biomarker, and the ability to offer GMP (good manufacturing practice)-approved quantities of ZAP-70. Upstate also has a facility in Dundee, Scotland. The company is a wholly owned subsidiary of Serologicals Corp. (Atlanta, GA, USA), a global leader in consumable biologic products.




Related Links:
Upstate

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Immunofluorescence Analyzer
IFA System
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.